ArticleScandinavian journal of immunology2026
Correlation Analysis Between Increased CD63 Expression Detected by Eosinophil Activation Test and sIgE Levels.
Article in Scandinavian journal of immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
This study evaluated the diagnostic utility of eosinophil activation testing in allergic rhinitis (AR) by monitoring CD63 and FcεRI expression on peripheral blood eosinophils before and after allergen stimulation. We enrolled 59 AR patients, 35 non-allergic rhinitis (NAR) patients, and 19 healthy controls (HC), stratified by sIgE results and clinical symptoms. Eosinophils were identified via flow cytometry as CCR3+ cells. We quantified baseline eosinophil counts and CD63/FcεRI expression, and then measured their changes following stimulation with 0.1 and 1.0 μg/mL dust mite allergen. Diagnostic accuracy was assessed using ROC analysis and Spearman's correlation with sIgE as the reference standard. AR patients had higher baseline eosinophil counts and CD63 expression than NAR or HC (p < 0.05). FcεRI was elevated in both AR and NAR relative to HC. Upon allergen stimulation, CD63 increased significantly only in AR, and this increase was dose-dependent (p < 0.05); FcεRI showed no response in any group. In this exploratory cohort, CD63 showed promising discriminatory ability, with an AUC of 0.899 (0.1 μg/mL) and 0.994 (1.0 μg/mL); a moderate positive correlation with sIgE was also observed (r = 0.358-0.461). In contrast, FcεRI performed around chance level (AUC 0.534-0.544). The eosinophil CD63 activation test can detect allergen-specific responses in AR and shows a moderate positive correlation with sIgE, suggesting potential as a complementary tool for AR diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.